Inhibrx Stock Alpha and Beta Analysis
| INBX Stock | USD 14.86 0.78 5.54% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Inhibrx. It also helps investors analyze the systematic and unsystematic risks associated with investing in Inhibrx over a specified time horizon. Remember, high Inhibrx's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Inhibrx's market risk premium analysis include:
Beta 0.64 | Alpha 0.0835 | Risk 3.14 | Sharpe Ratio 0.0115 | Expected Return 0.036 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Inhibrx |
Inhibrx Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Inhibrx market risk premium is the additional return an investor will receive from holding Inhibrx long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Inhibrx. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Inhibrx's performance over market.| α | 0.08 | β | 0.64 |
Inhibrx expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Inhibrx's Buy-and-hold return. Our buy-and-hold chart shows how Inhibrx performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Inhibrx Market Price Analysis
Market price analysis indicators help investors to evaluate how Inhibrx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Inhibrx shares will generate the highest return on investment. By understating and applying Inhibrx stock market price indicators, traders can identify Inhibrx position entry and exit signals to maximize returns.
Inhibrx Return and Market Media
The median price of Inhibrx for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 15.55 with a coefficient of variation of 6.18. The daily time series for the period is distributed with a sample standard deviation of 0.95, arithmetic mean of 15.42, and mean deviation of 0.72. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Mark Lappe of 26000 shares of Inhibrx at 15.29 subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Mark Lappe of 9500 shares of Inhibrx at 15.21 subject to Rule 16b-3 | 09/09/2024 |
3 | Acquisition by Mark Lappe of 8500 shares of Inhibrx at 15.19 subject to Rule 16b-3 | 09/10/2024 |
4 | Acquisition by Vuori Kristiina Md of 6457 shares of Inhibrx at 15.07 subject to Rule 16b-3 | 09/11/2024 |
5 | Acquisition by Mark Lappe of 26963 shares of Inhibrx at 15.05 subject to Rule 16b-3 | 09/12/2024 |
6 | Acquisition by Mark Lappe of 13037 shares of Inhibrx at 17.13 subject to Rule 16b-3 | 09/16/2024 |
7 | Acquisition by Vuori Kristiina Md of 6667 shares of Inhibrx at 15.0 subject to Rule 16b-3 | 10/03/2024 |
8 | Disposition of 15000 shares by Kayyem Jon Faiz of Inhibrx at 24.78 subject to Rule 16b-3 | 10/23/2024 |
9 | Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - BioSpace | 11/14/2024 |
10 | Acquisition by Kayyem Jon Faiz of 34843 shares of Inhibrx at 14.2269 subject to Rule 16b-3 | 11/19/2024 |
11 | Acquisition by Kayyem Jon Faiz of 18750 shares of Inhibrx at 14.1921 subject to Rule 16b-3 | 11/20/2024 |
About Inhibrx Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Inhibrx or other stocks. Alpha measures the amount that position in Inhibrx has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.001705 | 0.002089 | Price To Sales Ratio | 994.97 | 1.0K |
Inhibrx Upcoming Company Events
As portrayed in its financial statements, the presentation of Inhibrx's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inhibrx's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Inhibrx's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Inhibrx. Please utilize our Beneish M Score to check the likelihood of Inhibrx's management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Inhibrx
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.